Flt3-Itd Acute Myeloid Leukemia

The FDA granted priority review to quizartinib for treatment of certain patients with acute myeloid leukemia.

The FDA granted fast track designation to HM43239 for treatment of certain patients with acute myeloid leukemia.

Gilteritinib plus azacitidine conferred significantly higher complete remission rates, but similar OS, vs. azacitidine among patients with newly diagnosed, FLT3-mutated acute myeloid leukemia ineligible for intensive induction chemotherapy.

In this video, Alexander Edward Perl, MD, MS, spoke with Healio about a study assessing the outcome of patients with acute myeloid leukemia who received gilterintib with prior midostaurin or sorafenib therapy.

In this video, Richard M Stone, MD, professor of medicine at Harvard Medical School and director, translation research, adult leukemia program at Dana Farber Institute discusses three studies; one that looked at an irreversible inhibitor of FLT3 in patients with relapsed refractory acute myeloid leukemia (AML), and two studies that looked at approaches to Philadelphia and Philadelphia-like acute lymphoblastic leukemia. Stone highlighted the importance of the study on Adult Philadelphia-like B-cell ALL. "This is an important study because, if it is corroborated prospectively, it means that we can identify Philadelphia-like patients fairly easily with a fairly narrow panel of FISH-identifiable lesions.”

The FDA granted fast track designation to several agents under investigation for the treatment of patients with certain solid tumors or hematologic malignancies.

Sorafenib maintenance therapy reduced the risk for relapse and death after hematopoietic stem cell transplantation among a subset of patients with acute myeloid leukemia, according to study results published in Journal of Clinical Oncology.